Q-omics provides the consensus-scored FBXW12 profile across patient tissues and cancer cell-line models. FBXW12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FBXW12 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FBXW12 RNA expression shows 18,381 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where FBXW12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXW12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXW12 survival associations across molecular data types. FBXW12 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXW12 RNA expression–survival associations across cancer types. High FBXW12 expression shows unfavorable associations in KICH, DLBC and THCA, but favorable associations in ESCA, HNSC and UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for FBXW12 RNA expression.
This table summarizes FBXW12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXW12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXW12 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in BLCA, COAD and BRCA. The KIRC box plot shows higher FBXW12 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p < 0.001).
This table shows molecular features associated with FBXW12 in patient tissues and cancer cell lines. In patient samples, FBXW12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXW12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
